This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
AstraZeneca's Combination Therapy Meets Goal in Prostate Cancer Study
by Zacks Equity Research
Data from a late-stage study shows that treatment with a three-drug combo involving AZN's Truqap benefits patients with an aggressive form of prostate cancer.
J&J Seeks FDA Nod for Subcutaneous Tremfya as Induction Regimen in UC
by Zacks Equity Research
If approved, JNJ's Tremfya will be the first IL-23 inhibitor to offer a choice of subcutaneous or intravenous use as induction treatment in ulcerative colitis.
Pharma Stock Roundup: EU Nod for PFE's Hympavzi, NVS Ups Sales View
by Kinjel Shah
EU approval for PFE's hemophilia drug Hympavzi. Novartis upgrades its mid-term sales guidance.
Merck Stock Trades Near 52-Week Low: What's Next for Investors?
by Kinjel Shah
We believe investors with a long-term horizon should stay invested in MRK stock, while short-term investors should consider selling the same.
J&J Loses Around $24B in a Month: How to Play the Stock?
by Kinjel Shah
The decline in J&J's share price and the drug/biotech sector's downturn in the past month have left investors wondering if they should sell J&J stock.
Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Johnson & Johnson (JNJ). This makes it worthwhile to examine what the stock has in store.
CHMP Endorses J&J's Rybrevant-Lazcluze Combo for Use in NSCLC
by Zacks Equity Research
The CHMP's opinion is based on late-stage study data, which show that treatment with JNJ's combo drug reduces the risk of disease progression or death by 30% in certain NSCLC patients.
Pharma Stock Roundup: AZN, BAYRY's Earnings, ABBV's Pipeline Setback
by Kinjel Shah
AZN and BAYRY announce Q3 results. ABBV's studies on schizophrenia candidate, emraclidine, fail to meet goal.
Why Is Johnson & Johnson (JNJ) Down 6.7% Since Last Earnings Report?
by Zacks Equity Research
Johnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Bayer Q3 Earnings Miss Estimates, Nubeqa, Kerendia Boost Sales
by Zacks Equity Research
BAYRY's third-quarter earnings get affected due to impairment losses at the Crop Science division. Sales gain from the Pharmaceutical business's strong performance.
Will ISRG Stock Continue Its Uptrend After Gaining 9.9% in a Month?
by Indrajit Bandyopadhyay
Intuitive Surgical has maintained an uptrend so far this year on the back of robust da Vinci portfolio performance. The stock also gained during the past month. Let's see if the trend might change.
Should You Invest in the VanEck Pharmaceutical ETF (PPH)?
by Zacks Equity Research
Sector ETF report for PPH
Is iShares Core High Dividend ETF (HDV) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for HDV
TEVA Stock Down 7% Despite Q3 Earnings & Sales Beat, Guidance Increase
by Zacks Equity Research
TEVA reports better-than-expected third-quarter results, beating both earnings and sales estimates. However, the stock declines 7%.
Johnson & Johnson (JNJ) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Johnson & Johnson (JNJ) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Is Invesco S&P 500 Quality ETF (SPHQ) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for SPHQ
HALO Beats Q3 Earnings & Sales Estimates, Raises '24 View, Stock Up
by Zacks Equity Research
Halozyme reports better-than-expected third-quarter 2024 results. The company raises revenue guidance for 2024. Stock rises in after-hours trading.
The Zacks Analyst Blog Highlights Amazon.com, Johnson & Johnson, Boston Scientific and Armanino Foods of Distinction
by Zacks Equity Research
mazon.com, Johnson & Johnson, Boston Scientific and Armanino Foods of Distinction are part of the Zacks top Analyst Blog.
Top Stock Reports for Amazon.com, Johnson & Johnson and Boston Scientific
by Mark Vickery
Today's Research Daily features new research reports on 12 major stocks, including Amazon.com, Inc. (AMZN), Johnson & Johnson (JNJ) and Boston Scientific Corporation (BSX), as well as a micro-cap stock Armanino Foods of Distinction, Inc. (AMNF).
GSK Q3 Earnings Top, Stock Down on Lowered '24 View for Vaccine Sales
by Zacks Equity Research
GSK's Q3 earnings beat estimates but sales miss the same. The company also lowers its outlook for vaccine sales for the rest of the year due to weak U.S. demand.
AbbVie Trumps Q3 Earnings & Sales Estimates, Raises '24 EPS View
by Zacks Equity Research
ABBV's third-quarter 2024 earnings and sales beat estimates. The company increases the EPS guidance on encouraging product sales for immunology drugs.
Should Bioventus Stock Be in Your Portfolio Pre-Q3 Earnings?
by Sundeep Ganoria
Investors will likely focus on the sales performance of BVS across the Pain Treatments and Surgical Solutions franchises when it reports third-quarter results.
Should AbbVie Stock Be in Your Portfolio Pre-Q3 Earnings?
by Sundeep Ganoria
Investor focus will likely be on the sales performance of ABBV's blockbuster immunology drugs, Rinvoq and Skyrizi, when it reports third-quarter results this month.
Investors Heavily Search Johnson & Johnson (JNJ): Here is What You Need to Know
by Zacks Equity Research
Johnson & Johnson (JNJ) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Should iShares Core High Dividend ETF (HDV) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for HDV